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to normal control group (P < 0.01); S0 1 group and the
normal control group were no signiﬁcant difference
(P > 0.05); S0 1 group and S2 4 group were signiﬁcantly
different (P < 0.01); S0 1 group and end stage of cirrhosis
group were signiﬁcantly different (P < 0.01); S2 4 group
and end stage of cirrhosis group were signiﬁcantly
different (P < 0.01).
2. The correlation analysis between serum HBVDNA and liver
ﬁbrosis stage. There was no correlation between HBVDNA
level and liver ﬁbrosis stage (r = 0.140, P > 0.05).
3. The correlation analysis between serum HBVDNA and
AT1R mRNA. There was no correlation between HBVDNA
level and AT1RmRNA (r = 0.014, P > 0.05).
4. AT1 protein and AT1RmRNA are weakly or not expressed in
normal liver tissue, but are both obviously up-regulated in
ﬁbrotic or cirrhotic tissue, and the expressing intensities
are closely related to the degrees of ﬁbrotic stages.
Therefore, Ang II and AT1R through RAS activation could
play an important role during the onset and development
of liver ﬁbrosis.
5. Serum HBVDNA levels are neither related to ﬁbrotic
stages nor related to the expressions of AT1mRNA in
liver tissue.
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Background: It is difﬁcult to determine whether chronic HBV
infection patients with normal or paranormal ALT should to
be treated. Manifold factors should be considered befor
initiating antiviral therapy. Especially, liver biopsy may be
necessary for some cases. We reported Interferon treatment
for 4 cases with normal or paranormal ALT but in which liver
histologic exam showed G2 4 and/or S3 4.
Methods: 4 patients were male with an average age of
28 years (20–35). Mean ALT was 46.7 IU/L (36–59) and
HBVDNA level was 3--5 log10 copies/ml. Two patients were
HBeAg positive; one patient was both negative for HBeAg
and anti-HBe and one patient was anti-HBe positive. Liver
biopsy histological examination showed G2 in 3 patients,
G3 in 1 patients, S3 in 3 patients and S3--4 in 1 patient.
4 patients were treated with IFN-alpha (3 5 million IU,
3 times a week). Liver biopsy was taken after 1 year
treatment. In one patient, 8 extra months IFN and adefovir
combination therapy was taken and liver biopsy was taken
after combination treatment.
Results: All patients got normal Alt after 1 year treatment.
HBVDNA was undetectable in 3 patients. 2 patients with
initial positive HBeAg cleared HBeAg. But 3 patients still
were anti-HBeAg negative after 1 year treatment.Liver
biopsy histological examination after 1 year treatment
showed change fromG4 S3 4 to G2 S2 3 in 1 patient;
fromG2 S3 to G3 S4 in 1 patient and no change in the
other 2 patients.
Conclusions: All 4 patients we investigated are young and
with low HBVDNA level, normal or paranormal ALT, and
severe liver inﬂammation and ﬁbrosis in liver histology. Usu-
ally, antiviral treatment in chronic hepatitis B patients with
normal or paranormal ALT is not so effective. However, little
is known about the regimen and effect of antiviral treatment
in these patients with normal ALT but severe inﬂammation
and ﬁbrosis in histological examinations. In these 4 patients,
IFN was initially used. Though ALT and HBVDNA improved
after 1 year treatment, histological improvement is not
satisfying. 1 patient’s improvement in liver histology may
be due to seroconversion before Interferon therapy. For this
patient, Adefovir was added after 10 months of interferon
therapy. After 8 months of combination therapy we did liver
biopsy again. The other 3 patients were HBeAg negative,
but HBeAb were also negative, liver biopsy was taken 1year
later without combination of nucleoside analogs. Patients
were followed for further study.
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Objective: To investigate the effect of small interfering
RNA targeting connective tissue growth factor (CTGF) on
rats TGF-b/Smads signal.
